leadf
logo-loader
viewNaturally Splendid Enterprises Ltd.

Naturally Splendid Enterprises greenlit to begin Phase 2 study for its potential COVID-19 treatment

Biologic Pharmamedical CEO Franco Cavaleri tells Proactive the group, together with Naturally Splendid Enterprises Ltd (CVE:NSP) (OTCQB:NSPDF) has received a Notice of Authorization from Health Canada to proceed with a Phase 2 clinical trial for a potential COVID-19 treatment utilizing the target drug Cavaltinib. Cavaleri says within 60-90 days the company should be able to begin the trial. Cavaleri says he hopes Cavaltinib will show positive results in mitigating the 'cytokine storm' with COVID-19 patients

Quick facts: Naturally Splendid Enterprises Ltd.

Price: 0.065 CAD

TSX-V:NSP
Market: TSX-V
Market Cap: $13.11 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Naturally Splendid Enterprises Ltd. named herein, including the promotion by the Company of Naturally Splendid Enterprises Ltd. in any Content...

FOR OUR FULL DISCLAIMER CLICK HERE

Naturally Splendid adds another distributor for their plant-based food line...

Naturally Splendid (CVE: NSP- OTCQB: NSPDF) CEO Craig Goodwin joined Steve Darling from Proactive to bring news the company has found another distributor for their plant-based food product line called Natera. Goodwin telling Proactive Canadian based CANEX Foods which has been in operation since...

1 week, 4 days ago

2 min read